Not yet recruitingPHASE1, PHASE2NCT07000292
MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
Studying Glomerular disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Changzheng Hospital
- Principal Investigator
- Huji Xu, Ph.D, MDShanghai Changzheng Hospital
- Intervention
- Injection of MSC303(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- Shanghai Changzheng Hospital, Shanghai, Shanghai Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07000292 on ClinicalTrials.govOther trials for Glomerular disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06858319Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.Novartis Pharmaceuticals
- RECRUITINGPHASE4NCT05839314Effect of Huaier Granule on the Treatment of Idiopathic Membranous NephropathyChinese PLA General Hospital
- RECRUITINGNCT05505500Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.University of Michigan
- RECRUITINGNCT04528446The Impact of Glomerular Disorders on Bone Quality and StrengthColumbia University
- RECRUITINGNCT03929887KOrea Renal Biobank NEtwoRk System TOward NExt-generation AnalysisSeoul National University Hospital
- RECRUITINGNCT02954419IgA Nephropathy Biomarkers Evaluation Study (INTEREST)Sun Yat-sen University
- RECRUITINGPHASE2NCT00977977Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)